Developing Story: The Camizestrant Vote, Doctors Weigh In with Dr. Sarah Sammons & Dr. Neil Vasan

When the ODAC voted 6–3 against the camizestrant strategy, the headlines told you what happened — this episode tells you why. We're back for round two with Dr. Sarah Sammons, newly appointed Co-Leader of Breast Oncology at the University of Maryland Greenebaum Comprehensive Cancer Center, and Dr. Neil Vasan, Acting Chair of the ODAC and Director of Translational Research in Breast Cancer at NYU Langone Health, who sat in that room and cast one of the three yes votes. Alongside patient advocates Janice Cowden and Abigail Johnston, we break down the four FDA critiques that drove the vote, what the quality of life data showed and why regulators couldn't act on it, and what the FDA's new August 14th review deadline means for patients. Plus: why this science isn't going anywhere, and what ctDNA-guided treatment could look like in the very near future.